Atrion (NASDAQ:ATRI) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Atrion (NASDAQ:ATRI) in a research report report published on Tuesday morning. The brokerage issued a sell rating on the medical instruments supplier’s stock.

Atrion Stock Performance

Shares of ATRI opened at $453.63 on Tuesday. The stock has a 50 day moving average price of $453.34 and a 200 day moving average price of $408.58. Atrion has a one year low of $274.98 and a one year high of $593.00. The stock has a market capitalization of $798.39 million, a price-to-earnings ratio of 42.63 and a beta of 0.68.

Atrion (NASDAQ:ATRI) last issued its earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 EPS for the quarter. The business had revenue of $47.33 million during the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%.

Atrion Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Friday, June 14th were given a dividend of $2.20 per share. The ex-dividend date of this dividend was Friday, June 14th. This represents a $8.80 dividend on an annualized basis and a yield of 1.94%. Atrion’s payout ratio is 82.71%.

Institutional Trading of Atrion

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its holdings in shares of Atrion by 3.6% in the first quarter. BNP Paribas Financial Markets now owns 723 shares of the medical instruments supplier’s stock valued at $335,000 after purchasing an additional 25 shares during the period. Copeland Capital Management LLC grew its stake in shares of Atrion by 56.4% in the 4th quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 31 shares during the period. Harbor Investment Advisory LLC grew its stake in shares of Atrion by 33.1% in the 4th quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock valued at $72,000 after buying an additional 47 shares during the period. Quadrant Capital Group LLC acquired a new stake in shares of Atrion during the 4th quarter worth approximately $36,000. Finally, Oppenheimer Asset Management Inc. raised its position in shares of Atrion by 12.0% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 1,105 shares of the medical instruments supplier’s stock valued at $512,000 after buying an additional 118 shares during the period. 66.19% of the stock is currently owned by hedge funds and other institutional investors.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.